Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Novartis
(https://lutathera.com) 📸 Data Snapshot: May 31, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate) (https://lutathera.com)
GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
LUTATHERA is a treatment for SSTR+ GEP-NETs. Learn how LUTATHERA works, what makes it different, and see proven results. See full Prescribing & Safety Info.
HEADING_BODY GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate) (https://lutathera.com/patient-support/find-a-treatment-site/)
GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
LUTATHERA is a treatment for SSTR+ GEP-NETs. Learn how LUTATHERA works, what makes it different, and see proven results. See full Prescribing & Safety Info.
HEADING_BODY GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate) (https://lutathera.com/about-gep-net/early-action/)
GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
LUTATHERA is a treatment for SSTR+ GEP-NETs. Learn how LUTATHERA works, what makes it different, and see proven results. See full Prescribing & Safety Info.
HEADING_FOOTER GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate) (https://lutathera.com/sitemap/)
GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
LUTATHERA is a treatment for SSTR+ GEP-NETs. Learn how LUTATHERA works, what makes it different, and see proven results. See full Prescribing & Safety Info.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://lutathera.com) GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: An older woman stands in a white room, smiling into the distance. She has her hand raised in a high-five, and many hands reach out from the side to return the high-five. The headline next to her says: YOU GOT THIS 20,000+ patients chose LUTATHERA for the opportunity to delay NET progression––join in their strength The footnote next to her reads: Actor portrayal.] [H4] LUTATHERA has helped treat over 20,000 patients with NETs, including those: Who have just been diagnosed with faster-growing NETs (Ki-67, 10%–55% [grade 2 or 3]) and are ready for their first treatmentWho added LUTATHERA to their treatment after progressing on SSAs [H4] LUTATHERA can help slow down NET progression for longer. Choosing the right first treatment for you is a big step after diagnosis. You and your doctor can decide if LUTATHERA is the right first step to slow NET progression.See proven results with LUTATHERA [IMG: Early action icon.] [H2] Acting early to slow NETs is an important first stepSee why >NET, neuroendocrine tumor; SSAs, somatostatin analogues.
SUB-PAGE (https://lutathera.com/patient-support/find-a-treatment-site/) GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: An older woman stands in a white room, smiling into the distance. She has her hand raised in a high-five, and many hands reach out from the side to return the high-five. The headline next to her says: YOU GOT THIS 20,000+ patients chose LUTATHERA for the opportunity to delay NET progression––join in their strength The footnote next to her reads: Actor portrayal.] [H4] LUTATHERA has helped treat over 20,000 patients with NETs, including those: Who have just been diagnosed with faster-growing NETs (Ki-67, 10%–55% [grade 2 or 3]) and are ready for their first treatmentWho added LUTATHERA to their treatment after progressing on SSAs [H4] LUTATHERA can help slow down NET progression for longer. Choosing the right first treatment for you is a big step after diagnosis. You and your doctor can decide if LUTATHERA is the right first step to slow NET progression.See proven results with LUTATHERA [IMG: Early action icon.] [H2] Acting early to slow NETs is an important first stepSee why >NET, neuroendocrine tumor; SSAs, somatostatin analogues.
SUB-PAGE (https://lutathera.com/about-gep-net/early-action/) GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: An older woman stands in a white room, smiling into the distance. She has her hand raised in a high-five, and many hands reach out from the side to return the high-five. The headline next to her says: YOU GOT THIS 20,000+ patients chose LUTATHERA for the opportunity to delay NET progression––join in their strength The footnote next to her reads: Actor portrayal.] [H4] LUTATHERA has helped treat over 20,000 patients with NETs, including those: Who have just been diagnosed with faster-growing NETs (Ki-67, 10%–55% [grade 2 or 3]) and are ready for their first treatmentWho added LUTATHERA to their treatment after progressing on SSAs [H4] LUTATHERA can help slow down NET progression for longer. Choosing the right first treatment for you is a big step after diagnosis. You and your doctor can decide if LUTATHERA is the right first step to slow NET progression.See proven results with LUTATHERA [IMG: Early action icon.] [H2] Acting early to slow NETs is an important first stepSee why >NET, neuroendocrine tumor; SSAs, somatostatin analogues.
SUB-PAGE (https://lutathera.com/sitemap/) GEP-NET Treatment | LUTATHERA® (lutetium Lu 177 dotatate)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: An older woman stands in a white room, smiling into the distance. She has her hand raised in a high-five, and many hands reach out from the side to return the high-five. The headline next to her says: YOU GOT THIS 20,000+ patients chose LUTATHERA for the opportunity to delay NET progression––join in their strength The footnote next to her reads: Actor portrayal.] [H4] LUTATHERA has helped treat over 20,000 patients with NETs, including those: Who have just been diagnosed with faster-growing NETs (Ki-67, 10%–55% [grade 2 or 3]) and are ready for their first treatmentWho added LUTATHERA to their treatment after progressing on SSAs [H4] LUTATHERA can help slow down NET progression for longer. Choosing the right first treatment for you is a big step after diagnosis. You and your doctor can decide if LUTATHERA is the right first step to slow NET progression.See proven results with LUTATHERA [IMG: Early action icon.] [H2] Acting early to slow NETs is an important first stepSee why >NET, neuroendocrine tumor; SSAs, somatostatin analogues.
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 1 |
| /patient-support/find-a-treatment-site/ | 0 | 1 |
| /about-gep-net/early-action/ | 0 | 1 |
| /sitemap/ | 0 | 1 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@type": "Organization",
"@id": "https://us.lutathera.com/#Organization",
"name": "Novartis",
"url": "https://www.novartis.com/us-en/",
"logo": "https://usim.beprod.lutathera.com/sites/us_lutathera_com/files/icons/2026-02/logo.svg",
"description": "Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.",
"makesOffer": {
"@type": "Offer",
"@id": "https://us.lutathera.com/#makesOffer",
"name": "Lutathera",
"alternateName": "lutetium Lu 177 dotatate",
"availability": "https://schema.org/PrescriptionOnly",
"sameAs": "https://us.lutathera.com/patient-support/novartis-patient-support#offer"
}
}
/patient-support/find-a-treatment-site/
{
"@context": "https://schema.org",
"@type": "Organization",
"@id": "https://us.lutathera.com/#Organization",
"name": "Novartis",
"url": "https://www.novartis.com/us-en/",
"logo": "https://usim.beprod.lutathera.com/sites/us_lutathera_com/files/icons/2026-02/logo.svg",
"description": "Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.",
"makesOffer": {
"@type": "Offer",
"@id": "https://us.lutathera.com/#makesOffer",
"name": "Lutathera",
"alternateName": "lutetium Lu 177 dotatate",
"availability": "https://schema.org/PrescriptionOnly",
"sameAs": "https://us.lutathera.com/patient-support/novartis-patient-support#offer"
}
}
/about-gep-net/early-action/
{
"@context": "https://schema.org",
"@type": "Organization",
"@id": "https://us.lutathera.com/#Organization",
"name": "Novartis",
"url": "https://www.novartis.com/us-en/",
"logo": "https://usim.beprod.lutathera.com/sites/us_lutathera_com/files/icons/2026-02/logo.svg",
"description": "Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.",
"makesOffer": {
"@type": "Offer",
"@id": "https://us.lutathera.com/#makesOffer",
"name": "Lutathera",
"alternateName": "lutetium Lu 177 dotatate",
"availability": "https://schema.org/PrescriptionOnly",
"sameAs": "https://us.lutathera.com/patient-support/novartis-patient-support#offer"
}
}
/sitemap/
{
"@context": "https://schema.org",
"@type": "Organization",
"@id": "https://us.lutathera.com/#Organization",
"name": "Novartis",
"url": "https://www.novartis.com/us-en/",
"logo": "https://usim.beprod.lutathera.com/sites/us_lutathera_com/files/icons/2026-02/logo.svg",
"description": "Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.",
"makesOffer": {
"@type": "Offer",
"@id": "https://us.lutathera.com/#makesOffer",
"name": "Lutathera",
"alternateName": "lutetium Lu 177 dotatate",
"availability": "https://schema.org/PrescriptionOnly",
"sameAs": "https://us.lutathera.com/patient-support/novartis-patient-support#offer"
}
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
Novartis has 30.7 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: Novartis (lutathera.com)
This is a high-substance, low-BS clinical site that prioritizes regulatory transparency and specific medical data over marketing fluff. The few points deducted are purely for redundant content blocks across pages and the usage of standard pharmaceutical emotive imagery.
To achieve a near-zero score, the site should include direct DOI links or PubMed citations for the NETTER-1 and NETTER-2 clinical trials adjacent to the ‘20,000+ patients’ claim. It could also benefit from expanding the ‘proven results’ section with specific Kaplan-Meier survival curves or progression-free survival (PFS) percentages. Finally, ensuring the ‘Early Action’ sub-page contains unique body text distinct from the homepage template would eliminate repetition penalties.
The site content perfectly aligns with the Pharma & Biotech industry, specifically focusing on radiopharmaceutical treatments for Neuroendocrine Tumors (NETs). The presence of technical markers like Ki-67 indices and SSTR+ terminology confirms high industry relevance.
“The score of 10 is primarily driven by the 'Information Density' pillar (repetition of content blocks) and 'Commodity Fingerprint' (standard pharma value-prop clichés). The site scored perfectly in 'Semantic Coherence' and 'Identity and Authority' due to its rigorous alignment with Novartis's corporate footprint and the specific medical indications for Lutathera.”
This training module utilizes a snapshot of public data from Novartis, captured on May 31, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Novartis: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://lutathera.com to view the most current version of its content and learn from the source what this company is about and what it offers.